
A new approach shows that cancer patients can benefit from a simple bedside system that helps manage and reduce their pain levels, reveals a new study.
Pain affects half of all people with cancer and an estimated 80 percent of those with advanced cancer, causing both physical and emotional impact on patients.
Advertisement
‘Edinburgh Pain Assessment and management Tool (EPAT) is a simple way to manage pain and makes patients comfortable at all stages of cancer.’
Tweet it Now
Researchers at the University of Edinburgh worked with doctors to develop the Edinburgh Pain Assessment and management Tool (EPAT) - a pen and paper chart which medical staff use to regularly record pain levels in a simple traffic light system.
Amber or red pain levels indicating moderate or severe pain prompts doctors to review medications and side effects and monitor pain more closely.
The trial looked at pain levels in almost 2000 cancer patients over five days, following admission to regional cancer centers.
Patients whose care included use of the chart reported less pain during this time, compared with patients with standard care, who did not show an improvement.
Importantly, use of the chart was not linked to higher medicine doses. Authors suggest that it works by encouraging doctors to ask the right questions and reflect on pain medications and side effects more frequently, before patients reach a crisis point.
Researchers say the system is a simple way to put pain management at the forefront of routine care, but caution that more studies are needed to understand how it could work longer term.
The study was published in the Journal of Clinical Oncology and was funded by Cancer Research UK.
Professor Marie Fallon, of the Palliative and Supportive Care Group at the University of Edinburgh, said: "These exciting findings show the important benefits of influencing doctors' behaviors, rather than looking for more complex and expensive interventions. These findings are a positive step towards reducing the burden of pain for patients and making them as comfortable as possible at all stages of cancer."
Martin Ledwick, Head Information Nurse at Cancer Research UK, said: "In most cases it should be possible for cancer pain to be controlled if it is assessed and managed effectively. Any work that encourages medical teams to assess and monitor pain more carefully to help this happen has to be a good thing for patients."
Source: Eurekalert
Advertisement
The trial looked at pain levels in almost 2000 cancer patients over five days, following admission to regional cancer centers.
Patients whose care included use of the chart reported less pain during this time, compared with patients with standard care, who did not show an improvement.
Importantly, use of the chart was not linked to higher medicine doses. Authors suggest that it works by encouraging doctors to ask the right questions and reflect on pain medications and side effects more frequently, before patients reach a crisis point.
Researchers say the system is a simple way to put pain management at the forefront of routine care, but caution that more studies are needed to understand how it could work longer term.
The study was published in the Journal of Clinical Oncology and was funded by Cancer Research UK.
Professor Marie Fallon, of the Palliative and Supportive Care Group at the University of Edinburgh, said: "These exciting findings show the important benefits of influencing doctors' behaviors, rather than looking for more complex and expensive interventions. These findings are a positive step towards reducing the burden of pain for patients and making them as comfortable as possible at all stages of cancer."
Martin Ledwick, Head Information Nurse at Cancer Research UK, said: "In most cases it should be possible for cancer pain to be controlled if it is assessed and managed effectively. Any work that encourages medical teams to assess and monitor pain more carefully to help this happen has to be a good thing for patients."
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News

Lipid nanoparticles use M13, a potent anti-ulcerative colitis compound, in an oral formulation to combat colitis-linked cancer.

Shorter radiation course is just as good as the regular one for women choosing breast reconstruction after mastectomy, saving time and money.

HAMMR's small size permits minimally invasive implantation, monitoring cancer status, and dynamically adjusting immunotherapy, akin to a glucose monitor.

The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.

Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.